ArticleActa pharmacologica Sinica2024

SGLT2 inhibitor empagliflozin alleviates cardiac remodeling and contractile anomalies in a FUNDC1-dependent manner in experimental Parkinson's disease.

Wei Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.